Literature DB >> 7822028

Humoral and cell-mediated immunity to the Plasmodium falciparum ring-infected erythrocyte surface antigen in an adult population exposed to highly endemic malaria.

H P Beck1, I Felger, B Genton, N Alexander, F al-Yaman, R F Anders, M Alpers.   

Abstract

A parasitological and immunological survey was carried out in an area in Papua New Guinea highly endemic for malaria. Two hundred fourteen adult individuals were selected for studies to assess their immune responses against the malaria vaccine candidate ring-infected erythrocyte surface antigen (RESA). Total immunoglobulin G (IgG) antibodies directed against RESA as well as specific IgG1, IgG2, and IgG3 antibodies were determined. Humoral responses directed against RESA were frequent in all IgG subclasses. Only IgG3 responses were found to be age dependent. Total anti-RESA IgG antibodies were not correlated with protection against malaria as measured by parasite prevalence, parasite density, or health center attendance. In contrast, cytophilic antibodies (IgG1 and IgG3) were associated with reduced Plasmodium falciparum prevalence and reduced health center attendance. T-cell proliferation in general was low and very infrequent. No correlation between humoral and cellular immune responses could be found. Parasite density, parasite prevalence, and health center visits tended to be reduced in individuals with good humoral and cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822028      PMCID: PMC173038          DOI: 10.1128/iai.63.2.596-600.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Targeting of T-B interaction using heteroconjugate antibody.

Authors:  J L Davignon; M Vallin-Davignon; P L Cohen; R A Eisenberg
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion.

Authors:  J G Culvenor; K P Day; R F Anders
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

3.  Failure to detect MHC class II associations of the human immune response induced by repeated malaria infections to the Plasmodium falciparum antigen Pf155/RESA.

Authors:  M Troye-Blomberg; O Olerup; A Larsson; K Sjöberg; H Perlmann; E Riley; J P Lepers; P Perlmann
Journal:  Int Immunol       Date:  1991-10       Impact factor: 4.823

4.  Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria.

Authors:  D Pye; S J Edwards; R F Anders; C M O'Brien; P Franchina; L N Corcoran; C Monger; M G Peterson; K L Vandenberg; J A Smythe
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

5.  Cytotoxic T lymphocyte (CTL) low-responsiveness to the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: analysis of human CTL response to most known variants.

Authors:  D L Doolan; C Khamboonruang; H P Beck; R A Houghten; M F Good
Journal:  Int Immunol       Date:  1993-01       Impact factor: 4.823

6.  Isotypic analysis of Plasmodium falciparum-specific antibodies and their relation to protection in Madagascar.

Authors:  B Dubois; P Deloron; P Astagneau; C Chougnet; J P Lepers
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  Malaria and pregnancy in Cameroonian women. Naturally acquired antibody responses to asexual blood-stage antigens and the circumsporozoite protein of Plasmodium falciparum.

Authors:  J L Mvondo; M A James; A J Sulzer; C C Campbell
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Sep-Oct       Impact factor: 2.184

8.  Association between immune recognition of the malaria vaccine candidate antigen Pf155/RESA and resistance to clinical disease: a prospective study in a malaria-endemic region of west Africa.

Authors:  E M Riley; S J Allen; M Troye-Blomberg; S Bennett; H Perlmann; G Andersson; L Smedman; P Perlmann; B M Greenwood
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Jul-Aug       Impact factor: 2.184

9.  Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines.

Authors:  T L ten Hagen; A J Sulzer; M R Kidd; A A Lal; R L Hunter
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

Review 10.  The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies.

Authors:  M P Alpers; F al-Yaman; H P Beck; K K Bhatia; J Hii; D J Lewis; R Paru; T A Smith
Journal:  P N G Med J       Date:  1992-12
View more
  11 in total

1.  Isolation of peptides that mimic epitopes on a malarial antigen from random peptide libraries displayed on phage.

Authors:  C G Adda; L Tilley; R F Anders; M Foley
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria.

Authors:  J Eric Tongren; Christopher J Drakeley; Suzanna L R McDonald; Hugh G Reyburn; Alphaxard Manjurano; Watoky M M Nkya; Martha M Lemnge; Channe D Gowda; Jim E Todd; Patrick H Corran; Eleanor M Riley
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Familial correlation of immunoglobulin G subclass responses to Plasmodium falciparum antigens in Burkina Faso.

Authors:  C Aucan; Y Traoré; F Fumoux; P Rihet
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.

Authors:  L Wang; T L Richie; A Stowers; D H Nhan; R L Coppel
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria.

Authors:  Ervi Salwati; Gabriela Minigo; Tonia Woodberry; Kim A Piera; Harini D de Silva; Enny Kenangalem; Emiliana Tjitra; Ross L Coppel; Ric N Price; Nicholas M Anstey; Magdalena Plebanski
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

6.  Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria.

Authors:  David R Cavanagh; Daniel Dodoo; Lars Hviid; Jørgen A L Kurtzhals; Thor G Theander; Bartholomew D Akanmori; Spencer Polley; David J Conway; Kojo Koram; Jana S McBride
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Synthetic Antigens Derived from Plasmodium falciparum Sporozoite, Liver, and Blood Stages: Naturally Acquired Immune Response and Human Leukocyte Antigen Associations in Individuals Living in a Brazilian Endemic Area.

Authors:  Lilian Rose Pratt-Riccio; Daiana De Souza Perce-Da-Silva; Josué Da Costa Lima-Junior; Evelyn Kety Pratt Riccio; Marcelo Ribeiro-Alves; Fátima Santos; Mercia Arruda; Daniel Camus; Pierre Druilhe; Joseli Oliveira-Ferreira; Cláudio Tadeu Daniel-Ribeiro; Dalma Maria Banic
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

9.  Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens.

Authors:  Sreenivasulu B Reddy; Robin F Anders; Nadia Cross; Ivo Mueller; Nicolas Senn; Danielle I Stanisic; Peter M Siba; Mats Wahlgren; Fred Kironde; James G Beeson; Kristina E M Persson
Journal:  BMC Microbiol       Date:  2015-07-03       Impact factor: 3.605

10.  Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

Authors:  Christian Roussilhon; Claude Oeuvray; Christine Müller-Graf; Adama Tall; Christophe Rogier; Jean-François Trape; Michael Theisen; Aissatou Balde; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS Med       Date:  2007-11-13       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.